Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan in TCPC Patients (TEMPO)
NCT01292551Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Feb 2011
- Primary completion
- Mar 2013
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in single ventricle heart defect (SV) comparing Bosentan with Placebo (2 arms). Primary endpoint: Change from baseline in VO2max at 14 weeks. Started Feb 2011; status: completed.
02
Drugs
bosentan
03
Conditions
single ventricle heart defect (SV)
Beyond the preview
Go deeper on NCT01292551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01292551.